Somatropin
Somatropin is not a peptide. It is indexed alongside Growth factors and growth hormone-derived compounds because it appears in the same research literature and the same search demand; no statement on this site describes it as a peptide.
Identity
| Field | Value |
|---|---|
| Classification | Not a peptide |
| Primary class | Growth factors and growth hormone-derived compounds |
| CAS registry number | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| PubChem CID | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Molecular weight | Unknown PubChem returned no compound record for this name on the retrieval date, so this field is not sourced. |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Somatropin is recombinant human growth hormone, a 191-residue protein rather than a peptide, and it is indexed here because it is researched and searched alongside the compounds that stimulate its release. PubChem returned no compound record for the name. The Drugs@FDA register returned multiple approved biologics under this generic name; those products are recorded in the regulatory status field and are not what this page describes. A 1989 New England Journal of Medicine paper reports effects on body composition and metabolism in adults with growth hormone deficiency, and a 2013 Journal of Clinical Endocrinology and Metabolism workshop summary gives consensus guidelines for its use in that setting.
Other retrieved records include a 1990 Annals of Surgery paper on donor-site wound healing in severely burned children, a 1990 Journal of Clinical Endocrinology and Metabolism paper on short-term administration to elderly people, a 1996 Annals of Internal Medicine randomised trial in HIV-associated wasting, a 1999 paper on ten years of administration in adult growth hormone-deficient patients, a 2010 paper on long-term safety in children, and formulation papers from 1996 and 1998 on stabilisation of the protein.
[2, 3, 4, 5, 6, 7, 8, 9, 10]Reported mechanism
Recombinant human growth hormone; the retrieved records study it as replacement of the endogenous hormone, with body composition and metabolic endpoints.
[2, 3]Stated in the titles of the cited 1989 New England Journal of Medicine and 2013 Journal of Clinical Endocrinology and Metabolism papers.
Targets named in the cited records: growth hormone receptor, IGF-1 axis.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 5 application record(s) for this compound name (including BLA020280, BLA021148, BLA019774, BLA019640, BLA021426, marketed as GENOTROPIN PRESERVATIVE FREE, GENOTROPIN, NORDITROPIN FLEXPRO, NORDITROPIN NORDIFLEX, NORDITROPIN, ZOMACTON, BIO-TROPIN, HUMATROPE, OMNITROPE). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[1]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Somatropin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- recombinant human growth hormone
- rhGH
- HGH 191aa
Where this page sits
Research records
Cited research records for Somatropin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Sermorelin — GHRH analogues
- IGF-1 LR3 — Growth factors and growth hormone-derived compounds
- ACE-031 — Growth factors and growth hormone-derived compounds
Class page: Growth factors and growth hormone-derived compounds. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Somatropin?
Somatropin is recombinant human growth hormone, a 191-residue protein rather than a peptide, and it is indexed here because it is researched and searched alongside the compounds that stimulate its release. PubChem returned no compound record for the name.
Which class is Somatropin indexed under?
Somatropin is indexed under Growth factors and growth hormone-derived compounds. This class groups the growth factors, growth factor fragments and growth hormone-derived proteins that research-peptide catalogues list alongside the secretagogues, most of which are proteins rather than peptides and are labelled as such on their pages.
What does the FDA application register show for Somatropin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned 5 application record(s) for this compound name (including BLA020280, BLA021148, BLA019774, BLA019640, BLA021426, marketed as GENOTROPIN PRESERVATIVE FREE, GENOTROPIN, NORDITROPIN FLEXPRO, NORDITROPIN NORDIFLEX, NORDITROPIN, ZOMACTON, BIO-TROPIN, HUMATROPE, OMNITROPE). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.
Sources
- Drugs@FDA application register query for this compound, 5 application(s) returned: BLA020280, BLA021148, BLA019774, BLA019640, BLA021426. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:somatropin
- The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. The New England journal of medicine (1989). pmid:2687691
- GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. The Journal of clinical endocrinology and metabolism (2013). pmid:23543664
- Effects of recombinant human growth hormone on donor-site healing in severely burned children. Annals of surgery (1990). pmid:2121109
- Effects of short term administration of recombinant human growth hormone to elderly people. The Journal of clinical endocrinology and metabolism (1990). pmid:2298863
- Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Annals of internal medicine (1996). pmid:8967667
- The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. The Journal of clinical endocrinology and metabolism (1999). pmid:10443645
- Long-term safety of recombinant human growth hormone in children. The Journal of clinical endocrinology and metabolism (2010). pmid:19906787
- Stable formulations of recombinant human growth hormone and interferon-gamma for microencapsulation in biodegradable microspheres. Pharmaceutical research (1996). pmid:8899836
- Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. Journal of pharmaceutical sciences (1998). pmid:10189266
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.